This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mai, M. Articles by Liu, W. Search for Related Content PubMed PubMed Citation Articles by Mai, M. Articles by Liu, W.

Activation of p73 Silent Allel in Lung Cancer¹

Division of Experimental Pathology, Department of Laboratory Medicine and Pathology [M. M., A. Y., C. Q., D. I. S., W. L.], Department of Urology Research [A. Y., D. J. T.], and Department of Health Sciences Research [P. Y.], Mayo Foundation, Rochester, Minnesota 55905

p73, a first p53 relative, has recently been identified and demonstrated to be monoallelically expressed. This protein shows significant amino acid sequence and functional similarities to p53. However, it is unclear whether this protein functions as a tumor suppressor. To elucidate the role of p73 in tumor development, we investigated the expression of the p73 gene in lung cancer. In a comparison between normal lung and tumor tissues, p73 was more highly expressed in tumors. Moreover, using a C/T polymorphism in exon 2 for allele-specific expression analysis in 21 pairs of lung tumors and matched normal tissues, we found that five heterozygous samples exclusively expressed both alleles in tumors while showing monoallelic expression in matched normal tissues. This result was confirmed by single-nucleotide primer extension analysis. Mutation analysis of all 13 coding exons of the gene in 21 lung tumor DNAs revealed several polymorphisms, but no tumor-specific mutations were detected. These findings strongly suggest that p73 may play an important role in lung tumorigenesis through activation of a slient allele and overexpression of wild-type p73 rather than as a tumor suppressor.

¹ This work was supported by the Mayo Foundation, by NIH Grant CA 48031 (to D. I. S.), and National Cancer Institute Grant CA77118 (to P. Y.).

² To whom requests for reprints should be addressed, at Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: (507) 266-0508; Fax: (507) 266-5193; E-mail: liu.wanguo@mayo.edu.

Received 2/ 6/98. Accepted 4/16/98.

This article has been cited by other articles:

				J. Wang, Y.-X. Liu, M. P. Hande, A. C. Wong, Y. J. Jin, and Y. Yin TAp73 Is a Downstream Target of p53 in Controlling the Cellular Defense against Stress J. Biol. Chem., October 5, 2007; 282(40): 29152 - 29162. [Abstract] [Full Text] [PDF]

				H. Li, L. Yao, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Dong, B. Lin, J. Li, et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival Carcinogenesis, February 1, 2007; 28(2): 372 - 377. [Abstract] [Full Text] [PDF]

				G. Li, L.-E Wang, R. M. Chamberlain, C. I. Amos, M. R. Spitz, and Q. Wei p73 G4C14-to-A4T14 Polymorphism and Risk of Lung Cancer Cancer Res., October 1, 2004; 64(19): 6863 - 6866. [Abstract] [Full Text] [PDF]

				G. Li, E. M. Sturgis, L.-E. Wang, R. M. Chamberlain, C. I. Amos, M. R. Spitz, A. K. El-Naggar, W. K. Hong, and Q. Wei Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck Carcinogenesis, October 1, 2004; 25(10): 1911 - 1916. [Abstract] [Full Text] [PDF]

				U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]

				A Oniscu, N Sphyris, R G Morris, S Bader, and D J Harrison p73{alpha} is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes J. Clin. Pathol., May 1, 2004; 57(5): 492 - 498. [Abstract] [Full Text] [PDF]

				V. Vella, J. Zhu, F. Frasca, C.-Y. Li, P. Vigneri, R. Vigneri, and J. Y. J. Wang Exclusion of c-Abl from the Nucleus Restrains the p73 Tumor Suppression Function J. Biol. Chem., June 27, 2003; 278(27): 25151 - 25157. [Abstract] [Full Text] [PDF]

				S. Das, W. S. El-Deiry, and K. Somasundaram Regulation of the p53 Homolog p73 by Adenoviral Oncogene E1A J. Biol. Chem., May 9, 2003; 278(20): 18313 - 18320. [Abstract] [Full Text] [PDF]

				M. Guan, H.-X. Peng, B. Yu, and Y. Lu p73 Overexpression and Angiogenesis in Human Colorectal Carcinoma Jpn. J. Clin. Oncol., May 1, 2003; 33(5): 215 - 220. [Abstract] [Full Text] [PDF]

				T. Stiewe, J. Stanelle, C. C. Theseling, B. Pollmeier, M. Beitzinger, and B. M. Putzer Inactivation of Retinoblastoma (RB) Tumor Suppressor by Oncogenic Isoforms of the p53 Family Member p73 J. Biol. Chem., April 11, 2003; 278(16): 14230 - 14236. [Abstract] [Full Text] [PDF]

				E Pilozzi, C Talerico, A Platt, C Fidler, and L Ruco p73 gene mutations in gastric adenocarcinomas Mol. Pathol., February 1, 2003; 56(1): 60 - 62. [Abstract] [Full Text] [PDF]

				W. J. Freebern, J. L. Smith, S. S. Chaudhry, C. M. Haggerty, and K. Gardner Novel Cell-specific and Dominant Negative Anti-apoptotic Roles of p73 in Transformed Leukemia Cells J. Biol. Chem., January 17, 2003; 278(4): 2249 - 2255. [Abstract] [Full Text] [PDF]

				T. Stiewe, C. C. Theseling, and B. M. Putzer Transactivation-deficient Delta TA-p73 Inhibits p53 by Direct Competition for DNA Binding. IMPLICATIONS FOR TUMORIGENESIS J. Biol. Chem., April 12, 2002; 277(16): 14177 - 14185. [Abstract] [Full Text] [PDF]

				X.-F. Sun p73 Overexpression Is a Prognostic Factor in Patients with Colorectal Adenocarcinoma Clin. Cancer Res., January 1, 2002; 8(1): 165 - 170. [Abstract] [Full Text] [PDF]

				M. S. Irwin and W. G. Kaelin p53 Family Update: p73 and p63 Develop Their Own Identities Cell Growth Differ., July 1, 2001; 12(7): 337 - 349. [Full Text] [PDF]

				A. K. El-Naggar, S. Lai, G. L. Clayman, B. Mims, S. M. Lippman, M. Coombes, M. A. Luna, and G. Lozano p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas Carcinogenesis, May 1, 2001; 22(5): 729 - 735. [Abstract] [Full Text] [PDF]

				C.-L. Chen, S.-M. Ip, D. Cheng, L.-C. Wong, and H. Y. S. Ngan p73 Gene Expression in Ovarian Cancer Tissues and Cell Lines Clin. Cancer Res., October 1, 2000; 6(10): 3910 - 3915. [Abstract] [Full Text]

				B.-J. Park, S.-J. Lee, J. I. Kim, S.-J. Lee, C.-H. Lee, S.-G. Chang, J.-H. Park, and S.-G. Chi Frequent Alteration of p63 Expression in Human Primary Bladder Carcinomas Cancer Res., July 1, 2000; 60(13): 3370 - 3374. [Abstract] [Full Text]

				K. Hibi, B. Trink, M. Patturajan, W. H. Westra, O. L. Caballero, D. E. Hill, E. A. Ratovitski, J. Jen, and D. Sidransky AIS is an oncogene amplified in squamous cell carcinoma PNAS, May 9, 2000; 97(10): 5462 - 5467. [Abstract] [Full Text] [PDF]

				M.-J. Kang, B.-J. Park, D.-S. Byun, J.-I. Park, H.-J. Kim, J.-H. Park, and S.-G. Chi Loss of Imprinting and Elevated Expression of Wild-Type p73 in Human Gastric Adenocarcinoma Clin. Cancer Res., May 1, 2000; 6(5): 1767 - 1771. [Abstract] [Full Text] [PDF]

				Y. C. Cai, G.-y. Yang, Y. Nie, L.-D. Wang, X. Zhao, Y.-l. Song, D. N. Seril, J. Liao, E. P. Xing, and C. S. Yang Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53 Carcinogenesis, April 1, 2000; 21(4): 683 - 689. [Abstract] [Full Text] [PDF]

				F. Vikhanskaya, M. D'Incalci, and M. Broggini p73 competes with p53 and attenuates its response in a human ovarian cancer cell line Nucleic Acids Res., January 15, 2000; 28(2): 513 - 519. [Abstract] [Full Text] [PDF]

				S. Wienzek, J. Roth, and M. Dobbelstein E1B 55-Kilodalton Oncoproteins of Adenovirus Types 5 and 12 Inactivate and Relocalize p53, but Not p51 or p73, and Cooperate with E4orf6 Proteins To Destabilize p53 J. Virol., January 1, 2000; 74(1): 193 - 202. [Abstract] [Full Text]

				J. Roth and M. Dobbelstein Failure of viral oncoproteins to target the p53-homologue p51A J. Gen. Virol., December 1, 1999; 80(12): 3251 - 3255. [Abstract] [Full Text]

				K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]

				U. R. Peters, M. P. Tschan, K. A. Kreuzer, G. Baskaynak, U. Lass, A. Tobler, M. F. Fey, and C. A. Schmidt Distinct Expression Patterns of the p53-Homologue p73 in Malignant and Normal Hematopoiesis Assessed by a Novel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay and Protein Analysis Cancer Res., September 1, 1999; 59(17): 4233 - 4236. [Abstract] [Full Text] [PDF]

				S. Kawano, C. W. Miller, A. F. Gombart, C. R. Bartram, Y. Matsuo, H. Asou, A. Sakashita, J. Said, E. Tatsumi, and H. P. Koeffler Loss of p73 Gene Expression in Leukemias/Lymphomas Due to Hypermethylation Blood, August 1, 1999; 94(3): 1113 - 1120. [Abstract] [Full Text] [PDF]

				A. Tannapfel, M. Wasner, K. Krause, F. Geissler, A. Katalinic, J. Hauss, J. Mossner, K. Engeland, and C. Wittekind Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma J Natl Cancer Inst, July 7, 1999; 91(13): 1154 - 1158. [Abstract] [Full Text] [PDF]

				A. I. Zaika, S. Kovalev, N. D. Marchenko, and U. M. Moll Overexpression of the Wild Type p73 Gene in Breast Cancer Tissues and Cell Lines Cancer Res., July 1, 1999; 59(13): 3257 - 3263. [Abstract] [Full Text] [PDF]

				S.-G. Chi, S.-G. Chang, S.-J. Lee, C.-H. Lee, J. I. Kim, and J.-H. Park Elevated and Biallelic Expression of p73 Is Associated with Progression of Human Bladder Cancer Cancer Res., June 1, 1999; 59(12): 2791 - 2793. [Abstract] [Full Text] [PDF]

				M. Herranz, J. Santos, E. Salido, J. Ferna ndez-Piqueras, and M. Serrano Mouse p73 Gene Maps to the Distal Part of Chromosome 4 and Might Be Involved in the Progression of {{gamma}}-Radiation-induced T-cell Lymphomas Cancer Res., May 1, 1999; 59(9): 2068 - 2071. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The Emerging p53 Gene Family J Natl Cancer Inst, April 7, 1999; 91(7): 594 - 598. [Abstract] [Full Text] [PDF]

				M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro-oncol, April 1, 1999; 1(2): 124 - 137. [Abstract] [PDF]

				J. G. Falls, D. J. Pulford, A. A. Wylie, and R. L. Jirtle Genomic Imprinting: Implications for Human Disease Am. J. Pathol., March 1, 1999; 154(3): 635 - 647. [Abstract] [Full Text] [PDF]

				H. Tsao, X. Zhang, P. Majewski, and F. G. Haluska Mutational and Expression Analysis of the p73 Gene in Melanoma Cell Lines Cancer Res., January 1, 1999; 59(1): 172 - 174. [Abstract] [Full Text] [PDF]

				S. Strano, E. Munarriz, M. Rossi, B. Cristofanelli, Y. Shaul, L. Castagnoli, A. J. Levine, A. Sacchi, G. Cesareni, M. Oren, et al. Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73 J. Biol. Chem., September 15, 2000; 275(38): 29503 - 29512. [Abstract] [Full Text] [PDF]

				A. Zaika, M. Irwin, C. Sansome, and U. M. Moll Oncogenes Induce and Activate Endogenous p73 Protein J. Biol. Chem., March 30, 2001; 276(14): 11310 - 11316. [Abstract] [Full Text] [PDF]